Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 3/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 12/20 | 0.39 |
| ▸ | SHBG | P04278 | 1/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497527 | 1.00 | G6PD (0.46) | G6PDCYP19A1SHBGGPBAR1ABL1 | |
| SCHEMBL9172177 | 0.83 | ABL1 (0.47) | G6PDCYP19A1SHBGGPBAR1ABL1 | |
| SCHEMBL497634 | 0.82 | G6PD (0.61) | G6PDCYP19A1SHBGGPBAR1NR3C1 | |
| SCHEMBL6000815 | 0.81 | SHBG (0.47) | CYP19A1SHBGGPBAR1 | |
| SCHEMBL4438158 | 0.81 | SHBG (0.35) | CYP19A1SHBGGPBAR1SLC10A1NR3C1 | |
| SCHEMBL6804965 | 0.81 | SHBG (0.35) | CYP19A1SHBGGPBAR1SLC10A1NR3C1 | |
| SCHEMBL497582 | 0.81 | SHBG (0.35) | CYP19A1SHBGGPBAR1SLC10A1NR3C1 | |
| SCHEMBL7177293 | 0.81 | SHBG (0.56) | G6PDCYP19A1SHBGGPBAR1NR3C1 | |
| SCHEMBL7177299 | 0.81 | SHBG (0.56) | G6PDCYP19A1SHBGGPBAR1NR3C1 | |
| SCHEMBL7180772 | 0.81 | SHBG (0.56) | G6PDCYP19A1SHBGGPBAR1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129282-A1 | Pharmaceutical treatments and compositions | BIOVIE INC. | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129282-A1 | Pharmaceutical treatments and compositions | HSD3B1, HSD3B2, HSD17B1 | G6PD 506/4885CYP19A1 31/4885SHBG 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.